Abstract

INTRODUCTION

Neuroblastoma is a pediatric solid tumor that originated from the neural crest. The survival rate of these malignancies is below 50 %. The most common treatments for the disease have several adverse effects which makes them invasive for patients and limits the applicability as well as continuity of the treatment. Therefore, researchers seek new agents to reduce adverse effects in order to improve the treatment. In this wise, Plant-derived phytochemicals are promising drug candidates, such as carvacrol which has anti-cancer features on some cancers.

METHODS

Human neuroblastoma cell lines, KELLY (N-MYC positive) and SH-SY5Y (N-MYC negative)were grown in RPMI 1640 (KELLY) or DMEM (SH-SY5Y). Cells were treated with a range of concentration of carvacrol. Cellular proliferation was monitored by using xCELLigence Real-Time Cell Analyzer (RTCA) (ACEA Biosciences, Inc.) device to evaluate the anti-proliferative effect of carvacrol on the neuroblastoma cells.

RESULTS

Considering the proliferation curve of SH-SY5Y, results indicate that carvacrol has anti-proliferative effects on N-MYC negative neuroblastoma cells SH-SY5Y at all concentrations.

DISCUSSION AND CONCLUSION

The data illuminates that the carvacrol has an anti-proliferative role on neuroblastoma cells. In this context, this phyto-compound might be a promising agent for the malignancy.